AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04244448 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: receive solid form of BIKTARVY®
Description: The healthy volunteers will receive solid form of BIKTARVY® Pharmacokinetic samples will be taken at the following times: 0 hour (right before taking Biktarvy®); 0.5 hour; 1 hour; 1.5 hours; 2 hours; 2.5 hours; 3 hours; 4 hours; 8 hours; 12 hours; 24 hours; 36 hours; 48 hours and 72 hours (after Biktarvy®).
Study NCT03165617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QIVc
Description: Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains
Study NCT03165617 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-influenza Comparator Vaccine
Description: Non-influenza comparator vaccine for intramuscular use
Study NCT02443467 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03359538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
Study NCT03359538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
Study NCT03359538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
Study NCT00005975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate 20mg/day
Description: Double blinded Megestrol Acetate 20 mg/day
Study NCT00005975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate 40 mg/day
Description: Double blinded Megestrol Acetate 40 mg/day
Study NCT00005975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate Placebo 20 mg/day
Description: Megestrol Acetate Placebo 20 mg/day
Study NCT00005975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate Placebo 40 mg/day
Description: Megestrol Acetate Placebo 40 mg/day
Study NCT01480154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01480154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO
Study NCT04056819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells
Description: UMSC01 cells will be one single IC infusion followed by one single IV infusion with 12 months of follow up after treatment.
Study NCT02388243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention in Private Clinic
Description: The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing technics, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a private clinic.
Study NCT02388243 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening Results in Private Clinic
Description: At each private clinic, a support staff will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The support staff will provide the results of the BMI, physical activity and the ASSIST, and will offer a leaflet with further explanation about how to address problems with those lifestyles.
Study NCT04572308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T
Description: Patients will be treated with CD7 CAR-T cells~Biological: CD7 CAR-T; Drug: Cyclophosphamide,Fludarabine; Procedure: Leukapheresis;
Study NCT01153958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colposeptine
Description: Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
Study NCT01153958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days
Study NCT03299972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: 25 g whey protein supplementation twice daily (breakfast and lunch)
Study NCT03299972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 23.75 g maltodextrin twice daily (breakfast and lunch)
Study NCT03299972 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: 23.75 g maltodextrin twice daily (breakfast and lunch)
Study NCT03299972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 60 minutes of resistance exercise twice a week
Study NCT02670759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion of bupivacaine
Description: The infusion of local anesthetics will be initiated using a conventional infusion pump and will be transferred on a portable elastomeric pump before discharge from the hospital if the patient is discharged the day after surgery or at the latest on the second morning following surgery. The infusion will continue on the portable pump for 30 hours.
Study NCT03237624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Chitosan Chewing Gum
Description: Chitosan and chitosan-related preparations have been shown to have some antimicrobial properties, possibly in the disruption of bacterial colonization. It is thought that as a component of a functional chewing gum this will supplement in the removal of daily build up of dental plaque on tooth surfaces.
Study NCT03237624 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Chewing Gum
Description: Control chewing gum device does not have food additive chitosan in its composition.
Study NCT03237624 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral hygiene measures
Description: Patients will be given instructions on how to brush and floss routinely (twice per day)
Study NCT03237624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene measures
Description: Patients will be given instructions on how to brush and floss routinely (twice per day)
Study NCT04133883 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound, Haemophilia Joint Health Score
Description: Systematic joint examinations of ankles, knees and elbows
Study NCT02670759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single dose of bupivacaine
Description: A single dose of bupivacaine will be administered at the end of surgery before skin closure.
Study NCT02341027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jadelle
Description: within 5 days of delivery and before discharge from hospital
Study NCT04819126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Virtual Reality Application
Description: The training group was trained with games from different categories such as balance and aerobic exercises with a Nintendo Wii virtual reality device 2 times a week for a period of 6 weeks, with 1 session lasting for 30 minutes.
Study NCT02004236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tRNS Fronto-temporal cortex
Description: This group receive 35 sessions of tRNS over fronto-temporal cortex
Study NCT02004236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tRNS over fusiform temporal cortex
Description: This group receive 35 sessions of tRNS over fusiform temporal cortex
Study NCT02004236 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tRNS with sham
Description: the subjects receive 35 session with sham
Study NCT02400216 — intervention group
Intervention type: DRUG
Intervention: dual cholate
Description: test for defining disease severity
Study NCT05622630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four-cell bath
Description: Four-cell bath:Treatment with direct current
Study NCT05622630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gravel bath
Description: Gravel bath:In this procedure, the patients are given a footbath with heated stones (granules) of different sizes for a period of 20 minutes, during which the patients are encouraged to move their feet (and, if applicable, hands) evenly.
Study NCT00773448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comprehensive computed tomography of the abdomen/pelvis
Description: Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.
Study NCT00773448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limited Malignancy Screening
Description: 1) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)~In women, a pap smear/pelvic examination (if > 18 and \< 70 years old and not performed during the past year),a mammogram (> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (>40 years old) will be performed if not conducted in the past year.
Study NCT03113851 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: One lesion received radiotherapy for 35 Gy in 10 fractions and rested for one week; then another metastatic lesion were treated with radiotherapy for 35 Gy in 10 fractions.
Study NCT03113851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Description: Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy
Study NCT00802581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circumferential spread of local anesthetic
Description: The anesthetist will ensure, under ultrasound guidance, that local anesthetic (1 mL of 1% lidocaine) surrounds the sciatic nerve.
Study NCT00802581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-circumferential spread of local anesthetic
Description: The anesthetist will perform a single shot injection of local anesthetic (1 mL of 1% lidocaine) near the sciatic nerve under ultrasound guidance, without ensuring circumferential spread around the nerve.
Study NCT02325934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stribild
Description: Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil
Study NCT02325934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild, crushed
Description: Crushed Stribild tablet
Study NCT02341027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jadelle
Description: 6-8 weeks (42-56 days) postpartum
Study NCT01780181 — intervention group
Intervention type: DRUG
Intervention: TCM
Description: TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
Study NCT02929953 — intervention group
Intervention type: OTHER
Intervention: chart review
Description: data from charts and from registries will be compared
Study NCT04527952 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online handouts describing how to follow each diet for 1 week each
Description: Participants will receive handouts via email about how to follow each diet
Study NCT04527952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online handouts describing how to follow each diet for 1 week each
Description: Participants will receive handouts via email about how to follow each diet
Study NCT04435925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Loading dose: 0.5 mcg/kg Maintenance dose: 1 mcg/kg/minute
Study NCT04435925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Loading dose: 2 mcg/kg Maintenance dose: 0.4 mcg/kg/30-minutes
Study NCT02192515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 10 mg
Description: One tablet of APD356 10 mg will be orally administered in fasted state.
Study NCT02192515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 XR-20 mg
Description: One tablet of APD356 XR-20 mg will be orally administered in fasted state.
Study NCT02192515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 10 mg matching Placebo
Description: One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.
Study NCT02192515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 XR-20 mg matching Placebo
Description: One tablet of APD356 XR matching placebo will be orally administered in fasted state.
Study NCT02192515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 20 mg
Description: Two tablets of APD356 10 mg will be orally administered in fasted state.
Study NCT02192515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 20 mg matching Placebo
Description: Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.
Study NCT02192515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 XR-20 mg (orange tablet)
Description: One tablet of APD356 XR-20 mg orange tablet will be orally administered in fasted state.
Study NCT02192515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD356 XR-20mg (orange tablet, fed state)
Description: One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
Study NCT03485924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA with ROSE
Description: EUS-FNA with ROSE vs EUS-FNB without ROSE
Study NCT03485924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB without ROSE
Description: EUS-FNA with ROSE vs EUS-FNB without ROSE
Study NCT00333125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)
Description: One drop in the study eye(s) once daily, 9 PM, for 6 weeks
Study NCT00333125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)
Description: One drop in the study eye(s) twice daily for 6 weeks
Study NCT00333125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timolol Vehicle
Description: One drop in the study eye(s) once daily for 6 weeks
Study NCT01451606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week
Study NCT01451606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To serve as placebo for duloxetine. Administration schedule same as for active drug.
Study NCT02424396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL2
Description: Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2
Study NCT02424396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01243164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program
Description: The Wheelchair Skills Training Program will be administered in 2, 1 hour sessions.
Study NCT03986970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Pre-exposure prophylaxis
Study NCT04484961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR)
Description: The study group underwent normal ACL rehab modified by use of a tourniquet for blood flow restriction during selected exercises.
Study NCT01063049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gatorade/Miralax
Description: Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
Study NCT01063049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuLytely
Description: Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
Study NCT01063049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Description: Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy at 12 noon.
Study NCT01063049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
Study NCT01384981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulmonary rehabilitation
Study NCT01384981 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: pulmonary rehabilitation
Study NCT03019406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (GZ402666)
Description: Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV
Study NCT03019406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa (GZ419829)
Description: Pharmaceutical form: powder for concentrate for solution for infusion,~Route of administration: IV
Study NCT04055064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose control nutritional shake, nutrition education
Description: Participants in the treatment group were educated about improving their diet by consuming more low-fat high-quality protein sources, vegetables, complex carbohydrates and less simple carbohydrates. They were also instructed to consume two servings (474 ml) of a commercially produced Glucose Control Nutritional Shake between meals throughout the day for 12 weeks or until complete healing. The supplements provided a total of 500 kilocalories, 28 grams of high-quality protein and essential vitamins and minerals.
Study NCT01598766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 16 Channel SPEEDER Flex Coil
Description: This is a 16 element MRI coil, flexible, lightweight. Multiple uses.
Study NCT00774046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Induction: 3000mg/m2 IV infusion for day 1 and day 5~Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)
Study NCT00774046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Induction: 30mg/m2 after the end of HiDAC day 1 and day 5
Study NCT00774046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days
Study NCT00812994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: SSRI antidepressant
Study NCT00812994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00537394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: 90mg subcutaneously twice daily
Study NCT00537394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enfuvirtide
Description: 90mg subcutaneously twice daily
Study NCT00537394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg twice daily
Study NCT00537394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir
Description: 400 mg twice daily
Study NCT00537394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
Study NCT00537394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Darunavir
Description: Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
Study NCT00537394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Description: Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
Study NCT00537394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tipranavir
Description: Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)